Risk Factors for and Impact of Infection or Colonization with Aztreonam-resistant Pseudomonas Aeruginosa
Overview
Infectious Diseases
Nursing
Public Health
Affiliations
Objective: To identify risk factors for infection or colonization with aztreonam-resistant Pseudomonas aeruginosa and examine the impact of this organism on mortality.
Design: A case-control study was performed to identify risk factors for infection or colonization with aztreonam-resistant P. aeruginosa. A cohort study was subsequently performed to examine the impact of aztreonam resistance on outcomes.
Setting: A tertiary referral center in southeastern Pennsylvania.Participants. Inpatients with a clinical culture positive for P. aeruginosa between January 1, 1999, and December 31, 2000.
Results: Of 720 P. aeruginosa. isolates, 183 (25.4%) were aztreonam-resistant and 537 (74.6%) were aztreonam susceptible. In a multivariable model, prior fluoroquinolone use (adjusted odds ratio [aOR], 1.81 [95% confidence interval {CI}, 1.17-2.80]), prior use of an antianaerobic agent (aOR, 1.56 [95% CI, 1.06-2.29]), and renal insufficiency (aOR, 1.59 [95% CI, 1.10-2.29]) were associated with infection or colonization with aztreonam-resistant P. aeruginosa, while older age (aOR, 0.98 [95% CI, 0.97-0.99] per year of age) was negatively associated with infection or colonization with this organism. In-hospital mortality was higher among subjects infected or colonized with aztreonam-resistant P. aeruginosa, compared with those who were infected or colonized with aztreonam-susceptible P. aeruginosa (25.7% vs 16.8%; P=.009), but in multivariable analysis, no significant association was found between infection or colonization with aztreonam-resistant P. aeruginosa and mortality.
Conclusions: Curbing the use of fluoroquinolones and antimicrobials with antianaerobic activity may be an effective strategy to limit the emergence of aztreonam-resistant P. aeruginosa.
Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.
Zhen X, Stalsby Lundborg C, Sun X, Hu X, Dong H Antimicrob Resist Infect Control. 2019; 8:137.
PMID: 31417673 PMC: 6692939. DOI: 10.1186/s13756-019-0590-7.
Cobos-Trigueros N, Sole M, Castro P, Torres J, Hernandez C, Rinaudo M Crit Care. 2015; 19:218.
PMID: 25936721 PMC: 4432505. DOI: 10.1186/s13054-015-0916-7.
Rattanaumpawan P, Nachamkin I, Bilker W, Roy J, Metlay J, Zaoutis T J Antimicrob Chemother. 2015; 70(5):1547-51.
PMID: 25630645 PMC: 4398470. DOI: 10.1093/jac/dku548.
Optimizing empiric antibiotic therapy in patients with severe β-lactam allergy.
Koliscak L, Johnson J, Beardsley J, Miller D, Williamson J, Luther V Antimicrob Agents Chemother. 2013; 57(12):5918-23.
PMID: 24041892 PMC: 3837866. DOI: 10.1128/AAC.01202-13.
Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.
Schechner V, Temkin E, Harbarth S, Carmeli Y, Schwaber M Clin Microbiol Rev. 2013; 26(2):289-307.
PMID: 23554418 PMC: 3623381. DOI: 10.1128/CMR.00001-13.